Analysts See $0.46 EPS for MCBC Holdings, Inc. (MCFT); Careside (CASI)’s Sentiment Is 1.9

April 17, 2018 - By Winifred Garcia

MCBC Holdings, Inc. (NASDAQ:MCFT) Logo

Careside Inc (CASI) investors sentiment increased to 1.9 in Q4 2017. It’s up 0.76, from 1.14 in 2017Q3. The ratio is better, as 19 active investment managers opened new or increased holdings, while 10 sold and reduced their positions in Careside Inc. The active investment managers in our database now have: 3.56 million shares, up from 2.39 million shares in 2017Q3. Also, the number of active investment managers holding Careside Inc in top ten holdings was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 7 Increased: 8 New Position: 11.

Analysts expect MCBC Holdings, Inc. (NASDAQ:MCFT) to report $0.46 EPS on May, 10.They anticipate $0.34 EPS change or 283.33% from last quarter’s $0.12 EPS. MCFT’s profit would be $8.59M giving it 14.03 P/E if the $0.46 EPS is correct. After having $0.41 EPS previously, MCBC Holdings, Inc.’s analysts see 12.20% EPS growth. The stock increased 0.94% or $0.24 during the last trading session, reaching $25.82. About 60,880 shares traded. MCBC Holdings, Inc. (NASDAQ:MCFT) has risen 59.74% since April 17, 2017 and is uptrending. It has outperformed by 48.19% the S&P500.

MCBC Holdings, Inc., through its subsidiaries, innovates, designs, makes, and markets recreational sport boats in North America and internationally. The company has market cap of $482.29 million. The firm offers recreational performance sport boats, which are primarily used for water skiing, wakeboarding, and wake surfing, as well as general recreational boating. It has a 20.35 P/E ratio. It distributes its recreational performance sport boats under the MasterCraft brand name.

Among 8 analysts covering MCBC Holdings (NASDAQ:MCFT), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. MCBC Holdings had 23 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Friday, August 7 by SunTrust. The stock of MCBC Holdings, Inc. (NASDAQ:MCFT) earned “Strong Buy” rating by Raymond James on Tuesday, August 11. On Thursday, November 9 the stock rating was maintained by SunTrust with “Hold”. The firm earned “Overweight” rating on Tuesday, August 11 by KeyBanc Capital Markets. Wunderlich maintained the stock with “Buy” rating in Friday, May 27 report. The firm has “Buy” rating by FBR Capital given on Monday, January 29. The firm has “Neutral” rating given on Friday, August 7 by SunTrust. On Friday, February 9 the stock rating was maintained by B. Riley & Co with “Buy”. The firm has “Outperform” rating by Wells Fargo given on Tuesday, August 11. Robert W. Baird maintained MCBC Holdings, Inc. (NASDAQ:MCFT) on Thursday, February 8 with “Buy” rating.

The stock increased 4.37% or $0.285 during the last trading session, reaching $6.805. About 837,298 shares traded or 49.98% up from the average. CASI Pharmaceuticals, Inc. (CASI) has risen 181.56% since April 17, 2017 and is uptrending. It has outperformed by 170.01% the S&P500.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $541.96 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

Analysts await CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to report earnings on May, 21. They expect $-0.07 EPS, down 133.33% or $0.04 from last year’s $-0.03 per share. After $-0.08 actual EPS reported by CASI Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -12.50% EPS growth.

Wellington Shields & Co. Llc holds 0.78% of its portfolio in CASI Pharmaceuticals, Inc. for 445,118 shares. Wellington Shields Capital Management Llc owns 725,348 shares or 0.37% of their US portfolio. Moreover, Alpine Global Management Llc has 0.02% invested in the company for 27,729 shares. The Massachusetts-based Moors & Cabot Inc. has invested 0.01% in the stock. Perceptive Advisors Llc, a New York-based fund reported 83,682 shares.

MCBC Holdings, Inc. (NASDAQ:MCFT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: